drugset / Trial / NCT02414204

Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula

NCT02414204

RandomizedParallel-groupTriple-blindTreatment

Summary

Patients with stage IV and V chronic kidney disease and end stage renal disease requiring hemodialysis at University of Alabama at Birmingham (UAB) Dialysis Clinics will be recruited from the UAB Vascular Access Clinic, which has been the site for recruitment of patients requiring new vascular access for the last 10 years.

Timeline

Start
2015-04
Primary completion
2017-06-30
Completion
2018-06-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sildenafil Unknown 20 mg Oral

Indications

No indication recorded.